CAREER: Towards a stem cell-derived 3D human liver array for high-throughput screening

1351909药物引起的肝损伤(DILI)是人类急性肝功能衰竭和肝移植的主要原因，可能导致药物使用限制、药物黑箱警告以及药品上市前和上市后的损耗。除了对患者福祉的影响外，DILI的经济影响也是巨大的(将一种成功的药物推向市场需要大约10亿美元和12-15年的时间)。美国食品和药物管理局(FDA)要求的动物测试并不能完全代表人类的情况，因为动物和人类在肝脏功能上存在显著的进化差异。因此，利用人体细胞对化合物的潜在毒性进行临床前筛选现在构成了药物开发管道的关键部分。诱导多能干细胞来源的人肝细胞，称为肝细胞，不仅可以为筛选数百万种化合物提供近乎无限的细胞来源，而且还可以在未来实现个性化(针对患者)的药物筛选和治疗应用。然而，迄今为止创造的iHEs在功能上不像成人原代肝细胞(从供体肝脏分离)那么成熟，这是在临床试验中在活体患者身上测试药物之前充分预测临床结果所必需的。为了解决这一技术差距，研究人员将利用来自半导体(微芯片)行业的微制造工具，利用iHEPS和其他肝脏支持细胞类型设计出一种微型3D人体肝脏模型，该细胞在体外(体外)显示出功能成熟和稳定的几周。这种模拟肝脏将使用几个重要的标志来表征其相对于成人原代肝细胞的功能成熟度。此外，将探索肝脏模拟物是否能够提供有关DILI的临床有意义的信息，这是由于单一药物和多种药物治疗试图建立临床给药方案的模型。这位研究人员将把他的研究与教育项目相结合，旨在科罗拉多州立大学(CSU)和北科罗拉多地区新生的生物医学工程(BME)本科项目中建立一个导师和科学社区的连续统一体。特别是，调查员将设计和实施：a)一门新课程，让CSU BME大学生在正式的研究实验室环境中获得指导研究经验；b)一项循序渐进的计划，让高中生在BME的职业选择中获得机会，并最终在CSU BME实验室亲身体验暑期研究；以及c)反复学习模块，让K-6学生在课后计划中接触到科学和工程方面的进步。将开发的基于IHEP的3D人体肝脏模拟最终可能导致在药物开发的早期开发有效和安全的疗法，以增加临床成功的可能性，并限制患者接触不安全的药物。该平台还可用于评估污染环境的工业化学品的伤害潜力，促进更好地了解肝脏疾病的细胞/分子，以及帮助设计和实施个性化药物战略。更广泛地说，这种工程化的装置最终可以与其他组织模型集成到一个单一的集成系统中，提供对各种外源性侮辱的多器官(即全身)水平的理解。上述教育努力将建立一个强有力的机制，让不同年龄段的学生对科学和工程教育感兴趣，并让彼此参与到针对年轻学生的教学和实施计划中。由于该项目的跨学科性质，这个由CBET分部生物技术、生化和生物质工程计划颁发的职业奖项由生物基础设施部生物研究仪器开发计划共同资助。

1351909 Khetani, Salman R.Drug-induced liver injury (DILI) is a leading cause of acute liver failures and liver transplants in humans that can lead to restrictions on drug use, black-box warnings on drugs, and the pre-launch and post-market attrition of pharmaceuticals. In addition to its impact on the well-being of patients, the economic impact of DILI is significant (~$1B and 12-15 years to bring 1 successful drug to market). Animal testing that is required by the Food and Drug Administration (FDA) is not fully representative of the human condition due to significant and evolutionary differences between animals and humans in liver functions. Therefore, preclinical screening of compounds for potential toxicity using human cells now constitutes a critical part of the drug development pipeline. Induced pluripotent stem cell-derived human liver cells, called hepatocytes (iHeps), can not only provide a near unlimited source of cells for screening millions of compounds, but also enable personalized (patient-specific) drug screening and therapeutic applications in the future. However, iHeps created to date are not as functionally mature as adult primary hepatocytes (isolated from donor livers) which is required to adequately predict clinical outcomes before the drugs are tested on live patients in clinical trials. To address this technology gap, the investigator will utilize microfabrication tools adapted from the semiconductor (microchip) industry to engineer a miniaturized 3D human liver mimic using iHeps and other liver supportive cell types that displays functional maturity and stability for several weeks in vitro (outside the body). This liver mimic will be characterized using several important markers for its functional maturity relative to adult primary hepatocytes. Additionally, the liver mimic will be probed for its ability to provide clinically meaningful information on DILI due to single drug and multiple drug treatments in attempts to model clinical drug dosing regimens. The investigator will integrate his research with educational programs designed to build a continuum of mentorship and scientific community in the nascent biomedical engineering (BME) undergraduate program at Colorado State University (CSU) and in the Northern Colorado region. In particular, the investigator will design and implement: a) a new course that exposes CSU BME college students to mentored research experiences in a formal research laboratory setting; b) a step-wise program that exposes high school students to career options in BME and culminates in hands-on summer research experiences in CSU BME laboratories; and, c) recurrent learning modules that expose K-6 students in an after-school program to advances in science and engineering. The iHep-based 3D human liver mimic that will be developed could ultimately lead to the development of efficacious and safe therapeutics earlier in drug development towards increasing the likelihood of clinical success and limiting patient exposure to unsafe drugs. This platform may also be applicable for evaluating the injury potential of industrial chemicals that contaminate the environment, in promoting a better cellular/molecular understanding of diseases of the liver, and in helping to design and implement personalized medicine strategies. More broadly, the engineered device could ultimately be integrated with other tissue models into a single integrated system that provides a multi-organ (i.e. 'whole body') level of understanding of various exogenous insults. The aforementioned educational efforts will develop a robust mechanism to get students of different age groups interested in science and engineering education and to get each other involved in teaching and implementing programs for younger students.Due to the interdisciplinary nature of the project, this CAREER award by the Biotechnology, Biochemical, and Biomass Engineering Program of the CBET Division is co-funded by the Instrument Development for Biological Research Program of the Division of Biological Infrastructure.